Interactive effects of the ACE DD polymorphism with the NOS III homozygous G849T (Glu298→Asp) variant in determining endothelial function in coronary artery disease

Abstract

The products of nitric oxide synthase (NOS) and angiotensin-converting enzyme (ACE) play a critical role in determining vessel wall structure and function. Polymorphisms in both genes have been independently demonstrated to influence propensity to cardiovascular events. The purpose of this study was to determine the influence of the homozygous G849T(Glu298 Asp) polymorphism in NOS III on peripheral conduit artery endothelial function and to elucidate the modifier role, if any, of a common ACE polymorphism.

Three hundred and ninety-seven consecutive subjects presenting to the cardiac catheterization laboratory of the University of Michigan over a period of 18 months were recruited. DNA was extracted and polymerase chain reaction (PCR) analysis for ACE and NOS polymorphisms performed. Patients with homozygosity for G849T at both loci (TT) who belong to DD and II ACE genotype (groups 1 and 2) and those who are negative for this polymorphism (GG) and belong to either DD or II genotype (groups 3 and 4) were identified. The four groups then underwent determination of conduit endothelial function. Heterozygosity of Glu298-Asp or the ID variant of the ACE were not studied.

Median FMD value in the TT-DD group was 0.20 (-3.17, 2.01) compared with 2.23% (-0.29, 4.17) in the GG-II group. Median values in the TT-II and the GG-DD groups were 3.04 (-1.16, 6.61) and 2.46% (-1.83, 6.52) respectively. These values were not statistically significant (p > 0.05 by one-way ANOVA). Median nitroglycerin-mediated dilation in the four groups did not differ between the four groups (p = NS by ANOVA). Atherosclerosis burdens as assessed by angiography were not different across the groups.

In conclusion, the homozygous NOS III variant (GG) status does not seem to interact additively with the ACE homozygous DD genotype in determining flow-mediated vasodilation in individuals with established atherosclerosis and pre-existent endothelial dysfunction.

Keywords

ACE coronary artery disease endothelium nitric oxide synthase polymorphism

References

Suwaidi JA , Hamasaki S , Higano ST , Nishimura RA , Holmes DR, Jr. , Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-954.

Schachinger V , Britten MB , Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-1906.

Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997; 100: 2153-2157.

Pulkkinen A , Viitanen L , Kareinen A , Lehto S , Vauhkonen I , Laakso M. Intron 4 polymorphism of the endothelial nitric oxide synthase gene is associated with elevated blood pressure in type 2 diabetic patients with coronary heart disease. J Mol Med 2000; 78: 372-379.

Asanuma K , Yokoyama K , Tsukada T et al. An intron 4 gene polymorphism in endothelial cell nitric oxide synthase might modulate lipid metabolism in nondiabetic patients on hemodialysis. Nephron 2001; 88: 39-43.

Degen B , Schmidt S , Ritz E. A polymorphism in the gene for the endothelial nitric oxide synthase and diabetic nephropathy. Nephrol Dial Transplant. 2001; 16: 185-185.

Jachymova M , Horky K , Bultas J et al. Association of the Glu298Asp polymorphism in the endothelial nitric oxide synthase gene with essential hypertension resistant to conventional therapy. Biochem Biophys Res Commun 2001; 284: 426-430.

Sofowora G , Dishy V , Xie HG et al. In-vivo effects of Glu298Asp endothelial nitric oxide synthase polymorphism. Pharmacogenetics 2001; 11: 809-814.

Wattanapitayakul SK , Mihm MJ , Young AP , Bauer JA. Therapeutic implications of human endothelial nitric oxide synthase gene polymorphism. Trends Pharmacol Sci 2001; 22: 361-368.

10.

Hingorani AD , Liang CF , Fatibene J et al. A common variant of the endothelial nitric oxide synthase (Glu298->Asp) is a major risk factor for coronary artery disease in the UK. Circulation 1999; 100: 1515-1520.

11.

Tesauro M , Thompson WC , Rogliani P , Qi L , Chaudhary PP , Moss J. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci USA 2000; 97: 2832-2835.

12.

Tsukada T , Yokoyama K , Arai T et al. Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. Biochem Biophys Res Commun 1998; 245: 190-193.

13.

Wang XL , Mahaney MC , Sim AS et al. Genetic contribution of the endothelial constitutive nitric oxide synthase gene to plasma nitric oxide levels. Arterioscler Thromb Vasc Biol 1997; 17: 3147-3153.

14.

Rigat B , Hubert C , Alhenc-Gelas F , Cambien F , Corvol P , Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346.

15.

Cambien F , Evans A. Angiotensin I converting enzyme gene polymorphism and coronary heart disease. Eur Heart J. 1995; 16: 13-22.

16.

Lindpaintner K , Pfeffer MA , Kreutz R et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med. 1995; 332: 706-711.

17.

Keavney B , McKenzie C , Parish S et al. Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators. Lancet 2000; 355: 434-442.

18.

Arcaro G , Solini A , Monauni T et al. ACE genotype and endothelium-dependent vasodilation of conduit arteries and forearm microcirculation in humans. Arterioscler Thromb Vasc Biol 2001; 21: 1313-1319.

19.

Butler R , Morris AD , Burchell B , Struthers AD. DD angiotensin-converting enzyme gene polymorphism is associated with endothelial dys-function in normal humans. Hypertension 1999; 33: 1164-1168.

20.

Anderson TJ , Elstein E , Haber H , Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000; 35: 60-66.

21.

Bogaty P , Brecker SJ , White SE et al. Comparison of coronary angio-graphic findings in acute and chronic first presentation of ischemic heart disease. Circulation 1993; 87: 1938-1946.

22.

Anderson TJ , Uehata A , Gerhard MD et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26: 1235-1241.

23.

Rajagopalan S , Brook R , Mehta R , Supiano M , Pitt B. Effect of losartan in aging-related endothelial impairment. Am J Cardiol 2002; 89: 562-566.

24.

Shanmugam V , Sell KW , Saha BK. Mistyping ACE heterozygotes. PCR Methods Appl 1993; 3: 120-121.

25.

Dzau VJ. Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: 1047-1052.

26.

Gibbons GH. Cardioprotective mechanisms of ACE inhibition. The angiotensin II-nitric oxide balance. Drugs 1997; 54: 1-11.

27.

Guzik TJ , Black E , West NE et al. Relationship between the G894T polymorphism (Glu298Asp variant) in endothelial nitric oxide synthase and nitric oxide-mediated endothelial function in human atherosclerosis. Am J Med Genet 2001; 100: 130-137.

28.

Lembo G , De Luca N , Battagli C et al. A common variant of endothelial nitric oxide synthase (Glu298Asp) is an independent risk factor for carotid atherosclerosis. Stroke 2001; 32: 735-740.

29.

Shimasaki Y , Yasue H , Yoshimura M et al. Association of the mis-sense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction. J Am Coll Cardiol 1998; 31: 1506-1510.

30.

Kato N , Sugiyama T , Morita H et al. Lack of evidence for association between the endothelial nitric oxide synthase gene and hypertension. Hypertension 1999; 33: 933-936.

31.

Markus HS , Ruigrok Y , Ali N , Powell JF. Endothelial nitric oxide synthase exon 7 polymorphism, ischemic cerebrovascular disease, and carotid atheroma. Stroke 1998; 29: 1908-1911.

32.

Poirier O , Mao C , Mallet C et al. Polymorphisms of the endothelial nitric oxide synthase gene - no consistent association with myocardial infarction in the ECTIM study. Eur J Clin Invest 1999; 29: 284-290.

33.

Leeson CPM , Hingorani AD , Mullen MJ et al. Glu298Asp endothelial nitric oxide synthase gene polymorphism interacts with environmental and dietary factors to influence endothelial function. Circ Res 2002; 90: 1153-1158.